heartdiseasefacts.com
[ad_1]
February 20, 2024
2 minute read
Important points:
- Heart failure patients taking statins were less likely to develop any type of dementia.
- Statin use was also associated with a reduced risk of all-cause mortality.
Researchers found in a population-based study that statin use in older adults with heart failure was associated with a 20% lower risk of all-cause dementia, including a 28% lower risk of developing Alzheimer’s disease. It was reported that it showed.
The results also showed an 18% reduction in risk of vascular dementia, which was consistent across subgroups including age, gender, comorbidities, and education level, and showed that the cognitive benefits of statins are significant in patients with heart failure. This suggests that the disease may affect a wide range of groups.to Kai-Hang Yiu, MBBS, MD, PhD, MRCP, An assistant hospital director and his colleagues at the University of Hong Kong Shenzhen Hospital in China.
Image: Adobe Stock
“Given the strong association between heart failure and cognitive impairment and its various complications, potential strategies to reduce the risk of dementia in patients with heart failure are urgently needed,” Yiu et al. writing. Lancet Regional Health – Western Pacific. “Emerging evidence therefore suggests that higher LDL concentrations are associated with increased dementia risk, independent of vascular risk factors.”
Yiu et al. used the Hong Kong Clinical Data Analysis and Reporting System database to analyze data on 104,295 adults diagnosed with heart failure from 2004 to 2018. The mean age of the patients was 74 years. 50.3% were male. Researchers estimated the risk of all-cause dementia and its subtypes in adults prescribed statin therapy (n = 54,004) and adults not prescribed statins (n = 50,291). The primary outcome was incident dementia, including subtypes of Alzheimer’s disease, vascular dementia, and unspecified dementia, after heart failure diagnosis. The secondary outcome was all-cause mortality.
During a median follow-up of 9.9 years, 9.6% of patients were diagnosed with dementia. Of those, 2,250 had Alzheimer’s disease. 1,831 had vascular dementia and 5,950 had unspecified dementia. His 10-year cumulative incidence of overall dementia was 11% in non-statin users and 7.3% in statin users.
After applying inverse probability of treatment weighting, the researchers found that statin use was associated with a 20% lower risk of developing dementia than nonuse, with an adjusted subdistribution HR (aSHR) of 0.8 (95% CI, 0.76-0.84). ) was discovered.
In analyzes stratified by dementia subtype, statin use was associated with a 28% lower risk of Alzheimer’s disease (aSHR = 0.72, 95% CI, 0.63-0.82) and an 18% lower risk of vascular dementia. decreased (aSHR = 0.82, 95% CI). , 0.7-0.95) and 20% lower risk of unspecified dementia (aSHR = 0.8; 95% CI, 0.75-0.85).
Of the cohort, 60.4% died during follow-up. Statin use was associated with a 30% lower risk of all-cause mortality (HR = 0.7; 95% CI, 0.69-0.72).
“These findings provided compelling evidence that statins may utilize additional cognitive protective mechanisms beyond their lipid-lowering effects in reducing dementia risk,” the researchers said. are writing. “Mechanisms contributing to this protective effect may include, but are not limited to, anti-inflammatory effects, antioxidant effects, and modulation of amyloid-beta metabolism.”
The researchers noted that the findings may reflect a “prescription bias” in which patients with heart failure who are prescribed statins differ from those who do not receive such treatment. Furthermore, information on left ventricular ejection fraction was not available, and the researchers were unable to determine the exact dose of statin therapy for each patient.
[ad_2]
Source link
